重磅新药-肝癌患者的希望

  (Blockbuster drugs -Hope for liver cancer patients)

     刘平

恶性肿瘤种类繁多，机理复杂，治疗存在很大的困难和变数。肝癌又称癌中之王，到中晚期发现时已难于治愈。化疗药物从细胞毒性药物，发展到靶点药物，再进一步发展到多靶点药物。目前治疗肝癌的一线药物索拉非尼（2007年德国开发的治疗晚期肝癌的靶向药物）和仓伐替尼（2017年由日本卫材公司研发），其延长患者生命周期还比较短。长期酝酿的免疫疗法近些年爆发，像平静的湖水起了浪花，但在治疗种类和疗效上还需提高。因而，临床上开始将化疗药物和免疫疗法相互配合，期待提高疗效扩大瘤种。总体来讲，在肿瘤的治疗上有一定的进步，但困难依然巨大。

目前科学家对于肿瘤细胞的分子认识逐步深入，但是要想完全破解肿瘤细胞生命密码还要很长时间。现在科学家发现一个密码，就希望能籍此找到一种新药或新的疗法，我们把这种研究思路叫做发现密码，找到解药。由于肿瘤细胞的密码很多，因而可能的解药也纷繁复杂，究竟有多少密码，还是个未知数。况且，肿瘤的基因会不断突变，因而科学家要不停的研发新药以对付突变的基因，处于赛跑状态。

经过十分艰苦的研究历程，我们终于获得了一种全新抗肿瘤药物，具有如下特点：

1.本产品可列为1.1类抗癌新药。

经美国国立卫生研究院癌症研究所Scifinder查询，本产品是全新的，具有唯一性。

2.性能优异

该产品在细胞和动物实验中显示出高效、低毒、较广谱等优异性能：

(1)在随机的7种主要肿瘤瘤株的体外测试中优于紫杉醇。

(2)对人肝癌裸鼠移植瘤的抑制率超过85%，对小白鼠S-180移植瘤亦高抑制率，表明它具有很高的     药效，大幅超过国内外相关指标。

(3)毒性低。

(4)本产品纯度高，性能稳定，已经制成针剂。

3.机理优越

        (1)有效追踪肿瘤。

(2)多靶点攻击肿瘤。

(3)强力抑制肿瘤细胞分裂复制。

(4)信号作用强，肿瘤的凋亡率极高。

4.新的机制                          

根据该产品的结构特点，它会通过多种途径使肿瘤消亡，因而将产生肿瘤治疗全新的药物与机制。为保护知识产权具体内容以后公布。

   5.民生与市场概况：

这是一项”志在救人,心欲救世”的重要的民生项目。全世界2015年死于肝癌75万人。肝癌为亚洲华人第一大癌症，且目前尚无高效药物治疗。据保守估计，中国2015年超过40万人死于肝癌，福州

又是我国肝癌高发区之一。同时，全世界市场总共将达几十亿美金以上。如果加上我们产品对其它肿瘤的卓越治疗，其市场份额之大不可估量。预计将产生巨大的经济效益和深刻的民生效益。

6.本项目获2012年福建省首批留学人员来闽创业支持计划项目的优秀奖。

欢迎各界对该成果的转化。这是我们献给癌症患者和社会最好的礼物。

联系方式：pliu@fjirsm.ac.cn

2017.10.10

      Blockbusterdrugs -Hope for liver cancer patients

                                         Ping Liu

There are many kinds of malignant tumors and the mechanism iscomplex, so there are many difficulties and variables in the treatment. Livercancer is also called "king of cancer".It is difficult to cure at themiddle and late stages.Current treatment for liver cancerfirstline sorafenib in the treatment of advanced development (in Germa-ny in2007Targeted drugs for liver cancer) and Lenvima (developed in 2017 by theJapanese Eisai Co) extended patient life cycle is still relatively short. Long simmeringimmunotherapy has erupted in recent years, like calm waters rising above thewaves, but in the treatment category and the curative effect needs to beimproved. There-fore, chemotherapy and immunotherapy have been combined witheach other, we hope to improve the efficacy and expand the tumor species.Overall, there has been some progress in the treatment of cancer, but thedifficul-ties remain enormous.

At present, scientists have a deeper understanding of themolecular understanding of tumor cells, but it will take a long time tocompletely break the cell life code. Now that scientists have discovered acode, they hope to find a new medicine or new therapy here. The idea of thisresearch is called finding passwords and finding pass-words and finding antidotes. Because tumor cellshave a large number of passwords,the antidote is also numerousand complicated,how many passwords are still unknown. Moreover, tumor genes are constantlymutating, as a re-sult, scientists are constantly developing new drugs to fightmutant genes in a race.

After a very hard research process, we have finally acquired anew antitumor drug with the following characteristics:

1.This product can beclassified as the 1.1 category of anti-cancer drugs.

After enquiry with Scifinder in the Cancer Institute of theNational Institutes of Health, USA,the product is

brand new and uniqueness.

2.Excellent performance

The products showed high efficiency, low toxicity and broadspectrum in cell and animal experiments:

(1) It was superior to paclitaxel in the in vitro tests of 7random primary tumor strains.

(2) The inhibitory rate of nude mice transplanted with humanhepatocellular carcinoma was over 85%, and

the rate of inhibition of S-180tumor in mice was also high shows that it has a high efficacy, greatly  excee-           ding the relevant indicators at home and abroad.

(3) Toxicity was low.

(4) This product has high purity and stable performance. It hasbeen made into injection.

3. The mechanism is superior

(1) Tracking tumor effectively.

(2) Multi-target attacking tumor.

(3) Strongly inhibit the division and replication of tumorcells.

(4) Strong signal and high apoptosis rate.

4. New mechanisms:

According to the structural characteristics of the product, itwill cause the tumor to die out   througha variety

of ways.Thus, new drugs and mechanisms fortumor therapy will be produced. For the protection of intellec

-tual property rights, the specific content will be announced later.

5. People's livelihood andMarket Overview

This is an “Ambition to savepeople, the heart to save the world” important livelihood program. 75 thousand people die of liver cancer in the 2015 in the world.Liver cancer is the largest cancer in Asian Chinese, and there is no effectivedrug treatment. According to conservative estimates, in China over 400 thousand people died of livercancer in the2015, and Fuzhou is one of theareas with high inciden-ce of liver cancer in China. The world market will totalmore than $billions. If coupled with the remarka-ble treatment of our productsfor other cancers, the market share is immeasurable. It is expected to produce huge economic benefits and profound benefits for people's livelihood.

6.This project was Excellence Award of Fujian Province's first overseas students study program

in 2012.

Welcome all circles to thetransformation of the results. This is the best gift we give to cancer pati-         ents and society.

Contact information: pliu@fjirsm.ac.cn

2017.10.10